{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:56:19Z","timestamp":1793854579296,"version":"4.6.1"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejim.2026.107051","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:51:52Z","timestamp":1782939112000},"page":"107051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cardiovascular complications of antineoplastic treatment in prostate cancer patients and compensatory strategies for clinical management"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8667-5142","authenticated-orcid":false,"given":"Nikolaos","family":"Tsiamis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7495-1843","authenticated-orcid":false,"given":"Fotios","family":"Toulgaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8645-2102","authenticated-orcid":false,"given":"Eleni","family":"Stefanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-4514","authenticated-orcid":false,"given":"Christos","family":"Tountas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsitsinakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Maurogenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Kitsiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4695-3723","authenticated-orcid":false,"given":"Christo","family":"Kole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.107051_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejim.2026.107051_bib0002","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0003","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1177\/1557988318798279","article-title":"Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location","volume":"12","author":"Taitt","year":"2018","journal-title":"Am J Mens Health"},{"key":"10.1016\/j.ejim.2026.107051_bib0004","first-page":"15","article-title":"Emerging therapeutic strategies in prostate cancer: targeted approaches using PARP inhibition, PSMA-directed therapy, and androgen receptor blockade with olaparib, lutetium ((177)Lu)vipivotide tetraxetan, and abiraterone","author":"Kawczak","year":"2026","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5534\/wjmh.230177","article-title":"PARP inhibitors in the treatment of prostate cancer: from scientific rationale to clinical development","volume":"42","author":"Kwon","year":"2024","journal-title":"World J Mens Health"},{"key":"10.1016\/j.ejim.2026.107051_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231157632","article-title":"Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials","volume":"15","author":"Jang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0007","first-page":"14","article-title":"Androgen receptor signaling inhibition in advanced castration resistance prostate cancer: what is expected for the near future?","author":"Pozas","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejim.2026.107051_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217155","article-title":"Advances in and prospects of immunotherapy for prostate cancer","volume":"601","author":"Liu","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejim.2026.107051_bib0009","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030361","article-title":"The epidemiology of prostate cancer","volume":"8","author":"Pernar","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0010","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.107051_bib0011","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JOP.18.00178","article-title":"Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer","volume":"14","author":"Gupta","year":"2018","journal-title":"J Oncol Pract"},{"issue":"Suppl 1","key":"10.1016\/j.ejim.2026.107051_bib0012","first-page":"S3","article-title":"Androgen deprivation therapy in the treatment of advanced prostate cancer","volume":"9","author":"Perlmutter","year":"2007","journal-title":"Rev Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0013","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0014","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bju.14768","article-title":"Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial","volume":"125","author":"Sargos","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.ejim.2026.107051_bib0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0016","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2010.0014","article-title":"Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer","volume":"8","author":"Saylor","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejim.2026.107051_bib0017","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1756287215617872","article-title":"Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?","volume":"8","author":"Zareba","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0018","first-page":"129","article-title":"Cardiovascular effects of hormone therapy for prostate cancer","volume":"7","author":"Lester","year":"2015","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.ejim.2026.107051_bib0019","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bjp.0707624","article-title":"Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation","volume":"153","author":"Tsang","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejim.2026.107051_bib0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1530\/JOE-11-0441","article-title":"Testosterone modulates platelet aggregation and endothelial cell growth through nitric oxide pathway","volume":"213","author":"Campelo","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ejim.2026.107051_bib0021","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbrc.2004.04.054","article-title":"Testosterone is a potent inhibitor of L-type Ca(2+) channels","volume":"318","author":"Scragg","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejim.2026.107051_bib0022","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/aje\/kwr172","article-title":"Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third national health and nutrition examination survey and the multi-ethnic study of atherosclerosis","volume":"174","author":"Zhang","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ejim.2026.107051_bib0023","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/js.2018-00039","article-title":"Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer","volume":"2","author":"Gagliano-Juca","year":"2018","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ejim.2026.107051_bib0024","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","article-title":"Hypogonadism as a Reversible cause of torsades de pointes in men","volume":"138","author":"Salem","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.107051_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017267","article-title":"Impact of medical castration on malignant arrhythmias in patients with prostate cancer","volume":"10","author":"Hasegawa","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2026.107051_bib0026","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ando.2020.02.008","article-title":"Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes","volume":"82","author":"Salem","year":"2021","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ejim.2026.107051_bib0027","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/pros.24519","article-title":"Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study","volume":"83","author":"Wong","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.ejim.2026.107051_bib0028","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrurol.2016.273","article-title":"Cardiovascular toxicities of systemic treatments of prostate cancer","volume":"14","author":"Veccia","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0029","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2026.107051_bib0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-16-0200","article-title":"Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer","volume":"175","author":"Cheung","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejim.2026.107051_bib0031","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0032","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02","volume":"54","author":"Efstathiou","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0033","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","article-title":"Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses","volume":"40","author":"Hu","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2026.107051_bib0034","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2026.107051_bib0035","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2026.107051_bib0036","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0037","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/andr.12731","article-title":"Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? a meta-analysis and systematic review","volume":"8","author":"Liang","year":"2020","journal-title":"Andrology"},{"key":"10.1016\/j.ejim.2026.107051_bib0038","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00345-014-1439-6","article-title":"Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis","volume":"33","author":"Carneiro","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0039","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0040","doi-asserted-by":"crossref","DOI":"10.1038\/srep26220","article-title":"Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-\/-) mice","volume":"6","author":"Knutsson","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2026.107051_bib0041","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of Degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.107051_bib0042","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ejim.2026.107051_bib0043","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41391-022-00640-4","article-title":"Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-vigilance and food and drug administration databases entries","volume":"26","author":"Cicione","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejim.2026.107051_bib0044","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","article-title":"Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials","volume":"79","author":"Abufaraj","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0045","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003845","article-title":"A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer","volume":"95","author":"Sciarra","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejim.2026.107051_bib0047","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0048","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0049","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0050","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0051","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0052","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/pros.22965","article-title":"Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America","volume":"75","author":"Joshua","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.ejim.2026.107051_bib0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40885-019-0116-x","article-title":"Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis","volume":"25","author":"Zhu","year":"2019","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.ejim.2026.107051_bib0053","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0054","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0061","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0062","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0063","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejim.2026.107051_bib0070","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2026.107051_bib0071","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/heart.86.2.219","article-title":"Docetaxel induced cardiotoxicity","volume":"86","author":"Shimoyama","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2026.107051_bib0072","first-page":"417","article-title":"Docetaxel induced pericardial effusion","volume":"26","author":"Vincenzi","year":"2007","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejim.2026.107051_bib0073","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2026.107051_bib0076","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.15015","article-title":"Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale","volume":"88","author":"Sandhu","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2026.107051_bib0077","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0078","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA Trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytz230","article-title":"PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report","volume":"4","author":"Segan","year":"2020","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.ejim.2026.107051_bib0084","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2026.107051_bib0082","article-title":"Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejim.2026.107051_bib0091","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0092","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2026.107051_bib0096","first-page":"3","article-title":"Cardiotoxicity risk factors with immune checkpoint inhibitors","volume":"8","author":"Brumberger","year":"2022","journal-title":"Cardiooncology"},{"key":"10.1016\/j.ejim.2026.107051_bib0093","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.currproblcancer.2019.01.001","article-title":"Pericardial effusion due to pembrolizumab-induced immunotoxicity: a case report and literature review","volume":"43","author":"Atallah-Yunes","year":"2019","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.ejim.2026.107051_bib0094","first-page":"42","article-title":"Cardiac tamponade associated with pembrolizumab therapy in patient with pneumonectomy for lung cancer","volume":"105","author":"Berkowitz","year":"2022","journal-title":"R I Med J (2013)"},{"key":"10.1016\/j.ejim.2026.107051_bib0095","article-title":"Cardiac challenges in immune checkpoint therapy: complete heart block with pembrolizumab","volume":"16","author":"Sabanci","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejim.2026.107051_bib149","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/ehf2.13400","article-title":"Sipuleucel-T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database","volume":"8","author":"Moey","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ejim.2026.107051_bib0046","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0056","doi-asserted-by":"crossref","first-page":"84572","DOI":"10.18632\/oncotarget.20028","article-title":"Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials","volume":"8","author":"Moreira","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejim.2026.107051_bib0057","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0058","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopha.2018.02.067","article-title":"Abiraterone acetate in the treatment of prostate cancer","volume":"101","author":"Thakur","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejim.2026.107051_bib0059","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2026.107051_bib0064","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/COC.0b013e3182a790ce","article-title":"Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors","volume":"38","author":"Procopio","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0066","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clgc.2015.07.019","article-title":"Safety and clinical outcomes of abiraterone acetate after docetaxel in octogenarians with metastatic castration-resistant prostate cancer: results of the italian compassionate use named patient programme","volume":"14","author":"Maines","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejim.2026.107051_bib0067","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000519861","article-title":"Metastatic prostate cancer: treatment options","volume":"100","author":"Achard","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.ejim.2026.107051_bib0068","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate cancer: treatment advances and future directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejim.2026.107051_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1157306","article-title":"Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel","volume":"14","author":"Sousa-Pimenta","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejim.2026.107051_bib0074","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1254\/jphs.10279FP","article-title":"Mechanism of the cardioprotective effects of docetaxel pre-administration against adriamycin-induced cardiotoxicity","volume":"115","author":"Tomonari","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.ejim.2026.107051_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ejim.2026.107051_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2024.12.008","article-title":"Incidence and risk of thromboembolic and cardiovascular adverse events with PARP inhibitor treatment in patients with metastatic castration-resistant prostate cancer: a systematic review and safety meta-analysis","volume":"72","author":"Maiorano","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.ejim.2026.107051_bib0080","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00228-020-02913-0","article-title":"Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: a pharmacoepidemiological-pharmacodynamic study","volume":"76","author":"Montastruc","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2026.107051_bib0081","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.critrevonc.2018.08.011","article-title":"The Era of PARP inhibitors in ovarian cancer: \"Class Action\" or not? A systematic review and meta-analysis","volume":"131","author":"Staropoli","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejim.2026.107051_bib0085","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00280-019-03774-w","article-title":"Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer","volume":"83","author":"Moore","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejim.2026.107051_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1363848","article-title":"Mechanisms of torsades de pointes: an update","volume":"11","author":"Tsuji","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0087","doi-asserted-by":"crossref","first-page":"30772","DOI":"10.18632\/oncotarget.8956","article-title":"Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejim.2026.107051_bib0088","first-page":"17","article-title":"Immunotherapy-associated cardiotoxicity: current insights and future directions for precision cardio-oncology","author":"Stefanou","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejim.2026.107051_bib0089","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14712598.2024.2311750","article-title":"Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations","volume":"24","author":"Tsai","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ejim.2026.107051_bib0090","first-page":"197","article-title":"Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer","volume":"36","author":"Anassi","year":"2011","journal-title":"P T"},{"key":"10.1016\/j.ejim.2026.107051_bib0097","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0098","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejim.2026.107051_bib0099","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","article-title":"Safety analyses of the phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"85","author":"Chi","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0101","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.123.265448","article-title":"Renal and multiorgan safety of (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy","volume":"65","author":"Herrmann","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejim.2026.107051_bib0102","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/a-1332-8230","article-title":"Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors","volume":"60","author":"Jafari","year":"2021","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.ejim.2026.107051_bib0103","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107051_bib0104","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2026.107051_bib0105","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107051_bib0106","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2024.42.4_suppl.314","article-title":"A novel cardiovascular disease risk score for prediction of atherosclerotic disease events in men with prostate cancer","volume":"42","author":"Stabellini","year":"2024","journal-title":"Am Soc Clin Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0107","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0140-6736(22)02405-9","article-title":"Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study","volume":"401","author":"Tawfiq","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2026.107051_bib0108","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0109","doi-asserted-by":"crossref","first-page":"729","DOI":"10.23736\/S0393-2249.20.03797-2","article-title":"The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram","volume":"72","author":"De Nunzio","year":"2020","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.ejim.2026.107051_bib0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/pcan.2015.9","article-title":"Physical activity and its mechanistic effects on prostate cancer","volume":"18","author":"Wekesa","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejim.2026.107051_bib0111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.56434\/j.arch.esp.urol.20247701.1","article-title":"Effects of muscle strength training in prostate cancer: a systematic review","volume":"77","author":"Sande-Rivadulla","year":"2024","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0112","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4111\/kju.2015.56.1.12","article-title":"Metabolic effects of androgen deprivation therapy","volume":"56","author":"Choi","year":"2015","journal-title":"Korean J Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0113","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2026.107051_bib0114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030062","article-title":"Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors","volume":"7","author":"Mostaghel","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2026.107051_bib0115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41391-018-0045-x","article-title":"Serum cholesterol levels and tumor growth in a PTEN-null transgenic mouse model of prostate cancer","volume":"21","author":"Allott","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejim.2026.107051_bib0116","first-page":"61","article-title":"Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort","volume":"21","author":"Mondul","year":"2010","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ejim.2026.107051_bib0117","first-page":"15","article-title":"The effects of statins on prostate cancer patients receiving androgen deprivation therapy or definitive therapy: a systematic review and meta-analysis","author":"Hou","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejim.2026.107051_bib0118","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.27988","article-title":"Statin use in patients with advanced prostate cancer in the TITAN and SPARTAN trials","volume":"8","author":"Roy","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejim.2026.107051_bib0119","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.125.26387","article-title":"Primary prevention antihypertensive eligibility with the 2025 AHA\/ACC guideline","volume":"83","author":"Malik","year":"2026","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2026.107051_bib0120","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidemia s","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107051_bib0121","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107051_bib0122","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeag012","article-title":"SGLT-2 inhibitors in prevention of chemotherapy-induced cardiotoxicity: systematic review and meta-analysis","volume":"6","author":"Rafique","year":"2026","journal-title":"Eur Heart J Open"},{"key":"10.1016\/j.ejim.2026.107051_bib0123","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2559.2011.04033.x","article-title":"Prostate cancer and inflammation: the evidence","volume":"60","author":"Sfanos","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.ejim.2026.107051_bib0124","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107051_bib0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eururo.2019.07.031","article-title":"Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities","volume":"77","author":"Lu-Yao","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0126","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2016.12.025","article-title":"Management of prostate cancer in elderly patients: recommendations of a task force of the international society of geriatric oncology","volume":"72","author":"Droz","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejim.2026.107051_bib0127","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1093\/ckj\/sfad195","article-title":"Management of hypertension in patients with cancer: challenges and considerations","volume":"16","author":"Pandey","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ejim.2026.107051_bib0128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2022.0334","article-title":"Cardiovascular complications of treatment for prostate cancer","volume":"83","author":"Ferreira","year":"2022","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.ejim.2026.107051_bib0129","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1200\/JCO.2013.54.8875","article-title":"Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer","volume":"32","author":"Jacobs","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib0130","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1186\/s12885-019-6415-5","article-title":"Could aspirin be a lifesaver for prostate cancer patients in prostate cancer-specific mortality?: an update systematic review and meta-analysis","volume":"19","author":"Zhou","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejim.2026.107051_bib131","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107051_bib132","first-page":"763","article-title":"Hypertension: New Guidelines from the International Society of Hypertension","volume":"103","author":"Buelt","year":"2021","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ejim.2026.107051_bib133","article-title":"Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data","volume":"43","author":"Friedlander","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejim.2026.107051_bib134","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41391-020-0264-9","article-title":"Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist","volume":"24","author":"Margel","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejim.2026.107051_bib135","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CEJ.0000000000000075","article-title":"The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona","volume":"24","author":"Murta-Nascimento","year":"2015","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.ejim.2026.107051_bib136","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107051_bib137","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.107051_bib138","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.urolonc.2020.08.003","article-title":"Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer","volume":"39","author":"Morgans","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib139","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2026.107051_bib140","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ejim.2026.107051_bib141","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular imaging in contemporary cardio-oncology: a scientific statement from the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2026.107051_bib142","first-page":"677","article-title":"Strain imaging in cardio-oncology","volume":"2","author":"Liu","year":"2020","journal-title":"Cardio Oncology"},{"key":"10.1016\/j.ejim.2026.107051_bib143","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA cardio"},{"key":"10.1016\/j.ejim.2026.107051_bib144","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC Guidelines for the management of myocarditis and pericarditis","volume":"46","author":"Schulz-Menger","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107051_bib145","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2026.107051_bib146","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejim.2026.107051_bib147","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ejim.2026.107051_bib148","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart Rhythm"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T02:56:48Z","timestamp":1793588208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526003560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":149,"alternative-id":["S0953620526003560"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107051","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular complications of antineoplastic treatment in prostate cancer patients and compensatory strategies for clinical management","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107051"}}